A recent perspective study explores catheter therapies as an alternative treatment for patients with pulmonary arterial hypertension (PAH) who do not respond well to traditional medication. The paper, written by a researcher from the Division of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston, is titled “Catheter-Based Therapies for Patients With…
News
In a new study, researchers aimed to evaluate nerve distribution around the pulmonary artery — the effect of pulmonary artery denervation on an acute pulmonary hypertension porcine model — both in terms of arterial pressure and artery histology. The research paper, entitled “Pulmonary Artery Denervation Reduces Pulmonary Artery Pressure…
In a new study, researchers investigated if 3-D phase-contrast observations of wall shear stress (WSS) and oscillatory shear index (OSI) could effectively diagnose and evaluate pulmonary arterial hypertension (PAH) in patients, potentially leading to a markedly less invasive but accurate way of early disease diagnosis and management. The research paper, entitled “Low WSS and…
A new study identifies the hemodynamic variables that distinguish patients with idiopathic pulmonary arterial hypertension (PAH) from those with isolated post-capillary pulmonary hypertension (PH), a finding that will help to diagnose and treat more accurately and effectively patients with these disease subsets. The study, “Hemodynamic thresholds for pre-capillary pulmonary…
A recent review study has found that patients with HIV in Africa have a higher than average prevalence of developing pulmonary arterial hypertension (PAH). The study, entitled “HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment,” was published in the AIDS Research and…
In a new retrospective study, researchers show that a procedure called “palliative Senning” improves arterial oxygenation and life quality in children with congenital heart diseases and severe pulmonary hypertension (PH). The research paper, entitled “Palliative Senning in the Treatment of Congenital Heart Disease with Severe Pulmonary Hypertension,” was published in…
The Burbank, California-based non-profit phaware is a global association dedicated to creating awareness about pulmonary hypertension through engagement and technological innovation to discover and chart the course to a cure. Pulmonary hypertension (PH) is a rare, chronic lung disease that affects the functioning of the heart and can lead to fatal…
Complexa Inc., a biopharmaceutical company developing therapies to treat fibrosis and inflammation-related diseases, announced the successful completion of a Phase 1 clinical program of its lead drug candidate CXA-10, and the beginning of preparations for Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH) in 2016. The announcement builds…
Boehringer Ingelheim Pharmaceuticals, Inc. and the Pulmonary Fibrosis Foundation (PFF) have announced a five-year partnership in an effort to raise awareness for the disease and provide patients with disease education. Boehringer Ingelheim’s investment will also contribute to research funding of early diagnosis techniques and new therapies. Pulmonary Fibrosis (PF),…
The California Chapter of the Pulmonary Hypertension Association will host its Second Annual Long Beach O2 breathe Walk in Long Beach, California, on Saturday, Nov. 14, at 9 a.m. PT at El Dorado Regional Park. The event, dubbed the O2 breathe Walk, is a fundraising campaign that gathers together families, friends…
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops and commercializes drugs for the treatment of orphan diseases and conditions with ineffective current treatments, announced a new license agreement with a leading Japanese pharmaceutical company, Nippon Kayaku. Eiger BioPharmaceuticals aims to develop Nippon Kayaku’s therapeutic drug Bestatin™ (ubenimex) for the treatment of pulmonary…
A new study by Romanian and Belgian scientists sheds light on specific conditions associated with pulmonary hypertension (PH), and which of those conditions are associated with a better prognosis for survival. The report, titled “Is Right Ventricular Remodeling in Pulmonary Hypertension Dependent on Etiology? An Echocardiographic Study,”appeared in the…
